{"denomUnitsSelected":"Participants","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified by the protocol, the number of participants who discontinue study drug due to an AE will be reported for the overall study according to treatment arm, defined as a treatment sequence arm in the protocol (i.e., \"Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV\" and \"Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC\").","reportingStatus":"NOT_POSTED","timeFrame":"Up to ~24 months","title":"Number of Participants Who Discontinue Study Drug Due to an AE","type":"SECONDARY"}